TFS Capital’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

TFS Capital’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-10,048	Closed	-$95K	–	1226
2016 Q1	$95K	Buy	+10,048	New	+$81K	0.01%	897

Other funds holding ZYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

TFS Capital's ZYNE Position: Q2 2016 in Review

TFS Capital sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2016, closing a stake of 10,048 shares — an estimated $95K sold.

TFS Capital first reported a position in ZYNE in Q1 2016 and held it in 1 quarter. The position peaked at $95K in Q1 2016. 26 funds tracked by Wall St. Rank hold ZYNE as of Q2 2016.

TFS Capital reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2016 after selling out during the quarter.
TFS Capital sold 10,048 Zynerba Pharmaceuticals, Inc shares in Q2 2016, an estimated $95K.
TFS Capital first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2016 and held it in 1 quarter.
TFS Capital's Zynerba Pharmaceuticals, Inc position peaked at $95K in Q1 2016.
26 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.